Ablation of Atrial Fibrillation

Division of Cardiology, University of Utah Health Sciences Center, Salt Lake City 84132-2400, USA.
Current Problems in Cardiology (Impact Factor: 3). 06/2006; 31(5):361-90. DOI: 10.1016/j.cpcardiol.2006.01.002
Source: PubMed


Due in large part to the growing dissatisfaction with traditional pharmacologic approaches to atrial fibrillation (AF) management, and fueled by both the fruits of basic and clinical investigation into the nature of AF initiation and maintenance and the explosive development in catheter-based technologies, AF ablation has matured from a purely investigational technique to a viable--and often preferred--strategy for treating patients suffering from this arrhythmia. Future insights and developments will help us refine our treatment strategies, making AF ablation safer, faster, and more effective. As the prevalence of AF in the general population continues to expand, the goal of optimizing our approach to AF becomes ever more important--and more pressing.

3 Reads
  • Source
    • "Prevention of AF-related complications relies on antithrombotic therapy, control of ventricular rate, and adequate therapy of concomitant cardiac diseases. However, available drug therapy has major limitations, including incomplete effectiveness, cardiac and extracardiac toxicity and risk of life-threatening proarrhythmic complications (antiarrhythmic agents), and bleeding (anticoagulants) [8] [9] [10] [11]. Thus, there is a continuing need for new drugs, device, and ablative approaches to rhythm restoration, and simpler and safer stroke prevention regimens are needed for AF patients on life-long anticoagulation [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract atrial fibrillation (AF) is associated with a significant burden of morbidity and increased risk of mortality. Antiarrhythmic drug therapy remains a cornerstone to restore and maintain sinus rhythm for patients with paroxysmal and persistent AF based on current guidelines. However, conventional drugs have limited efficacy, present problematic risks of proarrhythmia and cause significant noncardiac organ toxicity. Thus, inadequacies in current therapies for atrial fibrillation have made new drug development crucial. New antiarrhythmic drugs and new anticoagulant agents have changed the current management of AF. This paper summarizes the available evidence regarding the efficacy of medications used for acute management of AF, rhythm and ventricular rate control, and stroke prevention in patients with atrial fibrillation and focuses on the current pharmacological agents.
    Cardiology Research and Practice 04/2011; 2011(1):874802. DOI:10.4061/2011/874802
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: While typical atrial flutter (AFL) is a characteristic macroreentrant atrial tachycardia originating in the right atrium, atrial fibrillation (AF) is triggered in most subjects by arrhythmogenic foci localized in the myocardium around pulmonary veins and maintained by functional reentrant circuits in the left atrial myocardium. However, there is a close relationship between the two arrhythmias. They often coexist in the same patient and may degenerate into each other [1]. The reasons for this coexistence are not clear. It is possible that pulmonary venous triggers also initiate AFL or convert AFL into AF [2].
    12/2006: pages 23-27;
  • Source

    Pacing and Clinical Electrophysiology 05/2007; 30(4):458-62. DOI:10.1111/j.1540-8159.2007.00693.x · 1.13 Impact Factor
Show more

Similar Publications